VITEK® 2 systems are designed to make your ID/AST workflow rapid and reliable, while still providing maximum flexibility and full traceability. Lab personnel can focus on using their expertise where it’s most needed.
Combining an innovative, automated platform with an expansive database, the VITEK® 2 microbial ID/AST testing system offers the confidence of fast, accurate results. Its smart design helps ensure better overall laboratory workflow with fewer repetitive tasks6-10 higher safety, improved standardization, and rapid time-to-results and reporting. 3, 6-8, 10
Leveraging lab expertise
Innovation in microbiology must never stop – because your lab challenges never stop. For more than 50 years, bioMérieux has shared your commitment to continually strengthen laboratory impact on patient therapy.
VITEK® 2 OPUS AST cards are part of our integrated ID AST** offer. Together with our blood culture offer, it meets your needs from the most routine to the truly challenging. Our offers let you leverage your expertise to deliver test results that enable the healthcare team to provide timely, appropriate therapy.
* AST: antimicrobial susceptibility testing
** ID/AST: identification and antimicrobial susceptibility testing
† Minimum software and firmware versions required
REFERENCES
1 - WHITE PAPER, 2008. Ergonomic Analysis Comparison of the VITEK® 2 and VITEK® 2 Compact with the Microscan WalkAway® 96 and Phoenix™ For Work Flow Efficiency and the Likelihood of Distal Upper Extremity Strain. Heller-Ono A.
2- Comparison of bioMerieux VITEK® 2 XL, BD Phoenix™, and Siemens MicroScan Walkaway® 96 plus: Choosing an Identification and Antimicrobial Susceptibility Testing System for a Medium Sized Microbiology Laboratory. Hooper M.1,2, Hill C.1,3, Hadwell V.1, Blondel-Hill E.1, 4. 1 Interior Health-Kelowna BC, 2 University of Victoria BC, 3 University of British Columbia-Okanagan, 4 University of British Columbia-Vancouver, Canada
3- Galar A., Yuste J.R., Espinosa M., Guillén-Grima F., Hernáez-Crespo S., and Leiva J. Clinical and economic impact of rapid reporting of bacterial identification and antimicrobial susceptibility results of the most frequently processed specimen types. Eur. J. Clin. Microbiol. Infect. Dis. 2012;31 (9):2445-2452
4- Galar A., Leiva J., Espinosa M., Guillén-Grima F., Hernáez S., Yuste JR. Clinical and economic evaluation of the impact of rapid microbiological diagnostic testing. J. of Infection 2012;65(4):302-309
5- Barenfanger J., Drake C., and Kacich G. Clinical and Financial Bene‑ ts of Rapid Bacterial Identi‑ cation and Antimicrobial Susceptibility Testing. J. Clin. Microbiol. 1999;37(5):1415-1418
6 - Ayats J., et. al. ASM 2007; Poster C-158.
7 - Blondel-Hill E., et. al. ICAAC 2006; Poster D-691.
8 - Eigner U., et. al. J Clin Microbiol, 2005; 43(8):3829.
9 - Heller-Ono A. bioMerieux White Paper, 2008.
10 - Hooper M., et. al. ECCMID 2013; Poster P-1536.